Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Presses On With US Tecfidera Launch ‘At Risk’

Follows First FDA Approval For Rival To MS Blockbuster

Executive Summary

Facing an appeal on a favorable US district court decision, Mylan has opted to launch the first generic Tecfidera in the US “at risk,” after obtaining FDA approval and seeing Biogen’s bid for injunctive relief shot down earlier this month.

You may also be interested in...



A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen

Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.

Biogen's US Tecfidera Sales Could Plunge By $2.8bn In 2021

Mylan’s “at-risk” launch of a generic version of Biogen’s Tecfidera could cost the originator dear as generic competition to the one of the most lucrative small-molecule opportunities arrives in the US.

Mylan Overcomes Biogen Bid For Tecfidera Injunction

Mylan is a step closer to realizing launch of a generic version of Biogen’s $3.3bn Tecfidera (dimethyl fumarate) multiple-sclerosis brand in the US after the originator was denied an injunction pending its appeal of an unfavorable patent decision at the district court level.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel